I'm an investment analyst with several years of clinical experience and a Master of Business Administration, now expanding my focus beyond biotech and healthcare into a range of sectors. Since 2017, I've had the privilege of sharing my insights on Seeking Alpha. My work emphasizes financial modeling techniques, such as Discounted Cash Flow (DCF) analysis, to uncover hidden assumptions within stock valuations across multiple industries. By deconstructing metrics like revenue growth rates and cash flow margin ...

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies1-3 Patients on Scemblix also had fewer dose reductions and half the rate of adverse reactions leading to treatment discontinuation1-3 Nearly 50% of CML patients do not meet efficacy milestones (MMR) with current SoC and almost 25% discontinue or switch therapies within o ...

Novartis AG (NYSE:NVS) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Richard Vosser - J.P. Morgan Emily Field - Barclays Capital Florent Cespedes - Bernstein Simon Baker - Redburn Atlantic Graham Parry - Bank of America Matthew Weston - UBS James Quigley - Goldman Sachs Peter Welford - Jefferies Etzer Darout - BMO Capital ...

Swiss pharma giant Novartis AG (NVS) reported better-than-expected results for the third quarter of 2024. Core earnings (excluding one-time charges) of $2.06 per share beat the Zacks Consensus Estimate of $1.94 and were up from $1.74 reported a year ago. The year-over-year growth was driven by an increase in sales. Revenues of $12.8 billion climbed 9% from the year-ago figure. On a constant currency basis, sales increased 10%, driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leq ...

For the quarter ended September 2024, Novartis (NVS) reported revenue of $12.82 billion, up 8.8% over the same period last year. EPS came in at $2.06, compared to $1.74 in the year-ago quarter.The reported revenue represents a surprise of +1.63% over the Zacks Consensus Estimate of $12.62 billion. With the consensus EPS estimate being $1.94, the EPS surprise was +6.19%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

Novartis Q3 Results | October 29, 2024 1 1 €Θ Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q3 2024 Results Q3 2024 Results Investor presentation October 29, 2024 Investor presentation October 29, 2024 ს NOVARTIS | This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "expected," "will ...

KEY TAKEAWAYSNovartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali.The Swiss pharmaceutical firm now forecasts 2024 core operating income growth of a high-teens percentage, compared with its previous target of a mid- to high-teens percentage.Novartis now projects full-year net sales to grow by a low-double-digit percentage, up from a high-single-digit percentage to low-double-digit percentage ...

For Immediate Releases Chicago, IL – October 29, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Novartis AG (NVS) , Reddit Inc. (RDDT) and Check Point Software Technologies Ltd. (CHKP) . Here are highlights from Tuesday's Analyst Blog: Buy 3 Stocks Likely to Gain on Q3 Earnings Beats We are in the first half of t ...

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc)Core operating income margin 40.1%, +340 basis points (cc), mainly driven by higher net sales Q3 operating income grew +123% (cc, +106% USD); net income up +121% (cc, +111% USD)Q3 core EPS grew +20% (cc, ...

Key TakeawaysMonte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion.The agreement is for Monte Rosa's MRT-6160 drug and other potential treatments for immune system diseases.Shares of Monte Rosa more than doubled on the news. Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its treatments ...